Hemoglobinopathy Treatment Drugs Market Structure And Its Segmentation For The Period 2027

Hemoglobinopathy Treatment Drugs Market

Hemoglobinopathy treatment is the only effective therapy for this chronic and debilitating disease. The treatments are broadly classified into non-drug and drug-based. The administration of drugs is dependent upon the severity of the disease. The growing prevalence of hemoglobinopathies such as thalassemia and sickle cell disease has increased the demand for hemoglobinopathy treatment drugs across the globe. As per the Centers for Disease Control and Prevention (CDC), sickle cell disease affects around 10,000 people in the U.S. every year. Hemoglobinopathy treatment drugs are typically used to treat sickle cell anemia, which could augment growth of the hemoglobinopathy treatment drugs market.

As far as regional impact is concerned, North America seems to be gaining significant traction in the hemoglobinopathy treatment drugs market. This is due to rapidly increasing product approvals by regulatory authorities across the U.S. On the contrary, Asia Pacific seems to be exhibiting a positive outlook due to rising cases of alpha thalassemia in emerging economies such as India and Thailand. Recently, in November 2019, Celegene Corporation received the U.S. Food and Drug Administration (FDA) approval for Reblozyl for the treatment of anemia in adult patients with beta-thalassemia.

Read More: https://bit.ly/3D0AYJ0

Comments

Popular posts from this blog

U.S. Meibomian Gland Dysfunction Market is growing rapidly with ThermaMEDx introducing a self-healing, disposable, pre-moistened, sterile cleaning eye-pad for use in treating the symptoms of dry eyes and meibomian gland dysfunction

Boston Sci Launched A New Device For Erectile Dysfunction Devices Market

Bakeable Trays Market Estimated To Develop At Cagr at 4.8% During Estimate Duration 2019-2027